Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Current Leases (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Current Leases for 3 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases fell 16.67% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 16.67% decrease, with the full-year FY2025 number at $3.0 million, down 16.67% from a year prior.
  • Current Leases was $3.0 million for Q4 2025 at Artiva Biotherapeutics, up from $75000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $3.7 million in Q2 2024 to a low of $75000.0 in Q3 2025.
  • A 3-year average of $2.2 million and a median of $3.3 million in 2025 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: rose 0.61% in 2024, then tumbled 36.97% in 2025.
  • Artiva Biotherapeutics' Current Leases stood at $3.6 million in 2023, then grew by 0.61% to $3.6 million in 2024, then fell by 16.67% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Current Leases are $3.0 million (Q4 2025), $75000.0 (Q3 2025), and $3.5 million (Q2 2025).